Carboplatin Treatment Options

A collection of 1666 research studies where Carboplatin is the interventional treatment. These studies are located in the United States. Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.

Home

All Treatments

Carboplatin

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

Study of Novel Treatment Combinations in Patients With Lung Cancer

NCT05633667

Recruiting

The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Arizona Oncology Associates,Substudy-01, Tucson, Arizona +87 locations

Arizona Oncology Associates,Substudy-01, Tucson, Arizona

Arizona Oncology Associates,Substudy-02, Tucson, Arizona

Rocky Mountain Cancer Center,Substudy-01, Denver, Colorado

Rocky Mountain Cancer Center,Substudy-02, Denver, Colorado

Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03, Fort Wayne, Indiana

Baptist Health Lexington,Substudy-03, Lexington, Kentucky

Washington University School of Medicine - Siteman Cancer Center,Substudy-01, Saint Louis, Missouri

Washington University School of Medicine - Siteman Cancer Center,Substudy-02, Saint Louis, Missouri

Washington University School of Medicine - Siteman Cancer Center,Substudy-03, Saint Louis, Missouri

Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri

Oncology Hematology Care Clinical Trials, LLC,Substudy-01, Cincinnati, Ohio

Oncology Hematology Care Clinical Trials, LLC,Substudy-02, Cincinnati, Ohio

Oncology Associates of Oregon, PC,Substudy-01, Eugene, Oregon

Oncology Associates of Oregon, PC,Substudy-02, Eugene, Oregon

Texas Oncology - Central South,Substudy-01, Austin, Texas

Texas Oncology - Central South,Substudy-02, Austin, Texas

US Oncology Investigational Products Center (IPC),Substudy-01, Fairfax, Virginia

US Oncology Investigational Products Center (IPC),Substudy-02, Fairfax, Virginia

Fred Hutchinson Cancer Center,Substudy-01, Seattle, Washington

Fred Hutchinson Cancer Center,Substudy-02, Seattle, Washington

Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03, Porto Alegre, Not set

Hospital Mae de Deus, Porto Alegre, Not set

Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Not set

Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03, São Paulo, Not set

Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03, São Paulo, Not set

Queen Mary Hospital,Substudy-01, Hong Kong, Not set

Queen Mary Hospital,Substudy-02, Hong Kong, Not set

Queen Elizabeth Hospital,Substudy-01, Hong Kong, Not set

Queen Elizabeth Hospital,Substudy-02, Hong Kong, Not set

Prince of Wales Hospital,Substudy-01, New Territories, Not set

Prince of Wales Hospital,Substudy-02, New Territories, Not set

Rambam Health Care Campus,Substudy-01, Haifa, Not set

Rambam Health Care Campus,Substudy-02, Haifa, Not set

Rambam Health Care Campus,Substudy-03, Haifa, Not set

Shaare Zedek Medical Center,Substudy-01, Jerusalem, Not set

Shaare Zedek Medical Center,Substudy-02, Jerusalem, Not set

Shaare Zedek Medical Center,Substudy-03, Jerusalem, Not set

Hadassah University Medical Center,Substudy-03, Jerusalem, Not set

Rabin Medical Center,Substudy-03, Petah Tiqva, Not set

Tel Aviv Sourasky Medical Center,Substudy-01, Tel Aviv-Yafo, Not set

Tel Aviv Sourasky Medical Center,Substudy-02, Tel Aviv-Yafo, Not set

Tel-Aviv Sourasky Medical Center,Substudy-03, Tel Aviv-Yafo, Not set

Chungbuk National University Hospital,Substudy-01, Cheongju-si, Not set

Chungbuk National University Hospital,Substudy-02, Cheongju-si, Not set

National Cancer Center,Substudy-01, Goyang, Not set

National Cancer Center,Substudy-02, Goyang, Not set

National Cancer Center,Substudy-03, Goyang, Not set

Chonnam National University Hwasun Hospital,Substudy-01, Gwangju, Not set

Chonnam National University Hwasun Hospital,Substudy-03, Gwangju, Not set

Seoul National University Bundang Hospital,Substudy-01, Gyeonggi-do, Not set

Seoul National University Bundang Hospital,Substudy-03, Gyeonggi-do, Not set

Kosin University Gospel Hospital,Substudy-01, Seo-gu, Not set

Kosin University Gospel Hospital,Substudy-03, Seo-gu, Not set

Severance Hospital, Yonsei University Health System,Substudy-03, Seoul, Not set

Asan Medical Center,Substudy-02, Seoul, Not set

Asan Medical Center,Substudy-03, Seoul, Not set

Asan Medical Centre,Substudy-01, Seoul, Not set

Samsung Medical Center,Substudy-01, Seoul, Not set

Samsung Medical Center,Substudy-02, Seoul, Not set

Samsung Medical Center,Substudy-03, Seoul, Not set

Severance Hospital, Yonsei University Health System,Substudy-01, Seoul, Not set

Severance Hospital, Yonsei University Health System,Substudy-02, Seoul, Not set

Seoul National University,Substudy-01, Seoul, Not set

Seoul National University,Substudy-02, Seoul, Not set

Korea University Guro Hospital,Substudy-01, Seoul, Not set

Korea University Guro Hospital,Substudy-03, Seoul, Not set

Changhua Christian Hospital,Substudy-01, Changhua City, Not set

Changhua Christian Hospital,Substudy-02, Changhua City, Not set

Changhua Christian Hospital,Substudy-03, Changhua City, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital,Substudy-01, Kaohsiung City, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital,Substudy-02, Kaohsiung City, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital,Substudy-03, Kaohsiung City, Not set

Kaohsiung Chang Gung Memorial Hospital,Substudy-01, Kaohsiung, Not set

Kaohsiung Chang Gung Memorial Hospital,Substudy-02, Kaohsiung, Not set

Kaohsiung Chang Gung Memorial Hospital,Substudy-03, Kaohsiung, Not set

National Taiwan University Hospital,Substudy-01, Taipei City, Not set

National Taiwan University Hospital,Substudy-02, Taipei City, Not set

Memorial Ankara Hospital,Substudy-03, Ankara, Not set

Dicle University Medical Faculty,Substudy-03, Diyarbakir, Not set

Necmettin Erbakan Universitesi,Substudy-03, Meram Konya, Not set

Gazi University Medical Faculty,Substudy-03, Yenimahalle, Not set

Birmingham Heartlands Hospital,Substudy-03, Birmingham, Not set

University Hospitals Birmingham NHS Trust,Substudy-01, Birmingham, Not set

University Hospitals Birmingham NHS Trust,Substudy-02, Birmingham, Not set

St James University Hospital,,Substudy-01, Leeds, Not set

St. Bartholomew's Hospital,Substudy-01, London, Not set

St. Bartholomew's Hospital,Substudy-02, London, Not set

St. Bartholomew's Hospital,Substudy-03, London, Not set

Conditions: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

Learn More ›

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

NCT05010629

Active Not Recruiting

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations

Conditions: Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma

Learn More ›

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984

Recruiting

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 350 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Banner MD Anderson Cancer Ctr /ID# 260129, Gilbert, Arizona +65 locations

Banner MD Anderson Cancer Ctr /ID# 260129, Gilbert, Arizona

City Of Hope Comprehensive Cancer Center /ID# 271295, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center /ID# 259884, Irvine, California

Yale New Haven Hospital /ID# 246647, New Haven, Connecticut

Georgetown University Hospital /ID# 255352, Washington, District of Columbia

University of Chicago /ID# 256334, Chicago, Illinois

Fort Wayne Medical Oncology and Hematology, Inc /ID# 260130, Fort Wayne, Indiana

University of Iowa Hospitals and Clinics /ID# 246638, Iowa City, Iowa

Barbara Ann Karmanos Cancer In /ID# 261799, Detroit, Michigan

Henry Ford Hospital /ID# 246648, Detroit, Michigan

START Midwest /ID# 251257, Grand Rapids, Michigan

St. Luke's Hosp. of Kansas City /ID# 259958, Kansas City, Missouri

Washington University-School of Medicine /ID# 246286, Saint Louis, Missouri

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 246303, New York, New York

Duke Cancer Center /ID# 246285, Durham, North Carolina

UH Cleveland Medical Center /ID# 246641, Cleveland, Ohio

Univ Oklahoma HSC /ID# 250884, Oklahoma City, Oklahoma

Tennessee Oncology, PLLC /ID# 246283, Nashville, Tennessee

University of Texas MD Anderson Cancer Center /ID# 246287, Houston, Texas

South Texas Accelerated Research Therapeutics /ID# 248946, San Antonio, Texas

University of Utah /ID# 246640, Salt Lake City, Utah

Northwest Medical Specialties - Tacoma /ID# 262801, Tacoma, Washington

Chris O'Brien Lifehouse /ID# 259087, Camperdown, New South Wales

The Kinghorn Cancer Centre /ID# 260874, Darlinghurst, New South Wales

Austin Health and Ludwig Institute for Cancer Research /ID# 255174, Heidelberg, Victoria

Peter MacCallum Cancer Ctr /ID# 259197, Melbourne, Victoria

Cancer Hospital - Chinese Academy Of Medical Sciences /ID# 270044, Beijing, Beijing

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 270038, Wuhan, Hubei

The first hospital of China medical University /ID# 270041, Shenyang, Liaoning

Shanghai Chest Hospital /ID# 270036, Shanghai, Shanghai

Shanghai East Hospital /ID# 268615, Shanghai, Shanghai

Shanghai Pulmonary Hospital /Id# 270039, Shanghai, Shanghai

Institut Bergonie /ID# 258655, Bordeaux, Gironde

Institut Gustave Roussy /ID# 260334, Villejuif Cedex, Val-de-Marne

Institut Régional du Cancer Montpellier /ID# 265086, Montpellier, Not set

Klinikum der Universitaet Muenchen - Campus Innenstadt /ID# 259412, Munich, Bayern

Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 259413, Berlin, Not set

Technische Universitat Dresden /ID# 259414, Dresden, Not set

Rambam Health Care Campus /ID# 255059, Haifa, H_efa

The Chaim Sheba Medical Center /ID# 254915, Ramat Gan, Tel-Aviv

Hadassah Medical Center-Hebrew University /ID# 255147, Jerusalem, Not set

Istituto Europeo Di Oncologia /ID# 256804, Milan, Milano

Fondazione IRCCS San Gerardo dei Tintori - Ospedale San Gerardo /ID# 258228, Monza, Monza E Brianza

National Cancer Center Hospital East /ID# 259417, Kashiwa-shi, Chiba

National Hospital Organization Shikoku Cancer Center /ID# 261279, Matsuyama, Ehime

Hokkaido Cancer Center /ID# 261278, Sapporo-shi, Hokkaido

Kyoto University Hospital /ID# 259419, Kyoto-shi, Kyoto

Shizuoka Cancer Center /ID# 261277, Sunto-gun, Shizuoka

National Cancer Center Hospital /ID# 259418, Chuo-ku, Tokyo

The Cancer Institute Hospital Of JFCR /ID# 260132, Koto-ku, Tokyo

Wakayama Medical University Hospital /ID# 260131, Wakayama-shi, Wakayama

National Cancer Center /ID# 248938, Goyang-si, Gyeonggido

CHA Bundang Medical Center /ID# 248939, Seongnam, Gyeonggido

Chonnam National University Hwasun Hospital /ID# 248943, Hwasun-gun, Jeonranamdo

Seoul National University Hospital /ID# 248940, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 248936, Seoul, Seoul Teugbyeolsi

Yonsei University Health System Severance Hospital /ID# 248937, Seoul, Not set

Hospital HM Nou Delfos /ID# 264851, Barcelona, Not set

Hospital Universitario Vall d'Hebron /ID# 258659, Barcelona, Not set

Hospital Santa Creu i Sant Pau /ID# 257294, Barcelona, Not set

Hospital Universitario Ramon y Cajal /ID# 257291, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz /ID# 257295, Madrid, Not set

Hospital Universitario 12 de Octubre /ID# 258658, Madrid, Not set

Hospital Universitario HM Sanchinarro /ID# 258657, Madrid, Not set

Hospital Universitario Virgen del Rocio /ID# 256940, Sevilla, Not set

Hospital Clinico Universitario de Valencia /ID# 257290, Valencia, Not set

Conditions: Advanced Solid Tumors

Learn More ›

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

NCT06077500

Recruiting

This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1) immunotherapy. The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with standard of care. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants get BI 764532 and d... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Orlando Health Cancer Institute, Orlando, Florida +21 locations

Conditions: Small Cell Lung Carcinoma (SCLC)

Learn More ›

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276

Recruiting

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Local Institution - 0337, Daphne, Alabama +189 locations

Local Institution - 0337, Daphne, Alabama

Local Institution - 0283, Hot Springs, Arkansas

Florida Cancer Specialists - South, Fort Myers, Florida

Mid Florida Hematology and Oncology Center, Orange City, Florida

Florida Cancer Specialists - North, Saint Petersburg, Florida

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia

Illinois Cancer Care, Peoria, Illinois

Local Institution - 0037, Minneapolis, Minnesota

University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico

Local Institution - 0029, Durham, North Carolina

Oncology Hematology Care, Cincinnati, Ohio

Local Institution - 0239, Cleveland, Ohio

Sanford Cancer Center, Sioux Falls, South Dakota

Local Institution - 0307, Knoxville, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Texas Oncology - Central/South Texas, Austin, Texas

Texas Oncology - Northeast Texas, Tyler, Texas

Oncology & Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia

Swedish Medical Center, Seattle, Washington

Local Institution - 0007, Tacoma, Washington

Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Buenos Aires

Local Institution - 0077, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0100, Buenos Aires, Ciudad Autónoma De Buenos Aires

Clinica Adventista Belgrano, Caba, Ciudad Autónoma De Buenos Aires

Instituto Médico Río Cuarto, Río Cuarto, Córdoba

GenesisCare - Campbelltown, Campbelltown, New South Wales

Local Institution - 0106, Penrith, New South Wales

Gallipoli Medical Research Ltd, Brisbane, Queensland

Grampians Health, Ballarat Central, Victoria

St. John of God Murdoch Hospital, Murdoch, Western Australia

Klinikum Wels-Grieskirchen GmbH, Wels, Oberösterreich

Medizinische Universität Graz, Graz, Steiermark

Kepler Universitätsklinikum, Linz, Not set

Landeskrankenhaus Rankweil, Rankweil, Not set

Local Institution - 0250, Wien, Not set

Local Institution - 0198, Brussels, Bruxelles-Capitale, Région De

Local Institution - 0091, Gent, Oost-Vlaanderen

Local Institution - 0187, Sint-Niklaas, Oost-Vlaanderen

Local Institution - 0180, Leuven, Vlaams-Brabant

Local Institution - 0092, Liège, Not set

Local Institution - 0166, Fortaleza, Ceará

Local Institution - 0165, Porto Alegre, Rio Grande Do Sul

Local Institution - 0169, Porto Alegre, Rio Grande Do Sul

Local Institution - 0170, Santa Cruz do Sul, Rio Grande Do Sul

Local Institution - 0163, Itajaí, Santa Catarina

Local Institution - 0178, Barretos, São Paulo

Local Institution - 0111, Sao Paulo, São Paulo

Local Institution - 0289, Edmonton, Alberta

CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi, Quebec

Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski, Rimouski, Quebec

IUCPQ, Quebec, Not set

Orlandi Oncologia, Santiago, Región Metropolitana De Santiago

Fundacion Arturo Lopez Perez (FALP), Santiago, Región Metropolitana De Santiago

Pontificia Universidad Catolica de Chile, Santiago, Región Metropolitana De Santiago

Bradfordhill, Santiago, Región Metropolitana De Santiago

Oncocentro Apys, Viña del Mar, Valparaíso

Local Institution - 0204, Beijing, Beijing

Local Institution - 0336, Beijing, Beijing

Local Institution - 0203, Chongqing, Chongqing

Local Institution - 0308, Fuzhou, Fujian

Local Institution - 0212, Xiamen, Fujian

Cancer Hospital of Shantou University Medical College, Shantou, Guangdong

Local Institution - 0227, Harbin, Heilongjiang

Local Institution - 0208, Wuhan, Hubei

Local Institution - 0209, Wuhan, Hubei

Local Institution - 0216, Changsha, Hunan

Local Institution - 0233, Nanchang, Jiangxi

Local Institution - 0244, Changchun, Jilin

Local Institution - 0235, Shenyang, Liaoning

Local Institution - 0335, Xi'an, Shaanxi

Shandong Cancer Hospital, Jinan, Shandong

Local Institution - 0206, Shanghai, Shanghai

Local Institution - 0210, Shanghai, Shanghai

Local Institution - 0330, Chengdu, Sichuan

Local Institution - 0213, Tianjin, Tianjin

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang

Local Institution - 0237, Hangzhou, Zhejiang

Local Institution - 0229, Linhai, Zhejiang

Shanghai East Hospital, Shanghai, Not set

Masarykuv onkologicky ustav, Brno, Brno-město

Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava, Ostrava Město

Local Institution - 0113, Prague, Praha 4

Local Institution - 0116, Olomouc, Not set

Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier, Hérault

Chu Grenoble Alpes, La Tronche, Isère

CHU Lille - Institut Coeur Poumon, Lille Cedex, Nord

L Hopital Nord Ouest, Gleize, Rhône

Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône

Centre Hospitalier Intercommunal de Créteil, Créteil, Val-de-Marne

Gustave Roussy, Villejuif, Val-de-Marne

Assistance Publique Hôpitaux de Marseille - Hôpital Nord, Marseille, Not set

Institut Curie, Paris, Not set

Centre Hospitalier de Cornouaille Quimper - Concarneau, Quimper, Not set

Institut für Klinisch Onkologische Forschung, Frankfurt, Hessen

Pius Hospital Oldenburg, Oldenburg, Niedersachsen

Klinikum Köln-Merheim, Köln, Nordrhein-Westfalen

Krankenhaus Martha-Maria Halle-Dölau, Halle, Sachsen-Anhalt

Local Institution - 0257, Bad Berka, Thüringen

Local Institution - 0263, Berlin, Not set

Asklepios Klinik Gauting GmbH, Gauting, Not set

LungenClinic Grosshansdorf, Grosshansdorf, Not set

Local Institution - 0260, Heidelberg, Not set

Robert Bosch Krankenhaus GmbH, Stuttgart, Not set

Errikos Dunant Hospital Center, Athens, Attikí

Local Institution - 0064, Athens, Attikí

Local Institution - 0062, Thessaloniki, Kentrikí Makedonía

European Interbalkan Medical Center, Thessaloniki, Thessaloníki

Local Institution - 0059, Larissa, Thessalía

Local Institution - 0278, New Delhi, Delhi

Local Institution - 0274, Bengaluru, Karnataka

Local Institution - 0271, Madurai, Tamil Nadu

Local Institution - 0277, Varanasi, Uttar Pradesh

Local Institution - 0273, Kolkata, West Bengal

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania

Local Institution - 0068, Milan, Lombardia

Istituto Nazionale Tumori Regina Elena, Rome, Roma

Local Institution - 0110, Perugia, Umbria

Casa di Cura Dott. Pederzoli, Peschiera del Garda, Verona

Local Institution - 0074, Bologna, Not set

Istituto Europeo di Oncologia IRCCS, Milano, Not set

National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime

Kurume University Hospital, Kurume, Fukuoka

Hokkaido University Hospital, Sapporo, Hokkaido

Kobe City Medical Center General Hospital, Kobe-shi, Hyogo

Kanazawa University Hospital, Kanazawa, Ishikawa

Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa

Sendai Kousei Hospital, Sendai, Miyagi

Nara Medical University Hospital, Kashihara city, Nara

Kurashiki Central Hospital, Kurashiki, Okayama

Kansai Medical University Hospital, Hirakata, Osaka

Local Institution - 0314, Osakasayama, Osaka

Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka

Saitama Medical University International Medical Center, Hidaka, Saitama

Local Institution - 0318, Ina-machi, Saitama

Hamamatsu University Hospital, Hamamatsu, Shizuoka

Local Institution - 0326, Bunkyo-ku, Tokyo

The Cancer Institute Hospital of JFCR, Koto, Tokyo

Fukushima Medical University, Fukushima, Not set

Local Institution - 0305, Cheongju-si, Chungcheongbuk-do [Chungbuk]

Local Institution - 0286, Seongnam, Kyǒnggi-do

Local Institution - 0304, Suwon-si, Kyǒnggi-do

Local Institution - 0285, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0293, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0309, Daegu, Taegu-Kwangyǒkshi

Local Institution - 0311, Kuching, Sarawak

Local Institution - 0310, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur

Local Institution - 0312, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur

Local Institution - 0148, Pachuca, Hidalgo

Local Institution - 0146, Guadalajara, Jalisco

Local Institution - 0147, Monterrey, Nuevo León

Local Institution - 0145, Puebla, Not set

Local Institution - 0097, Amsterdam, Noord-Holland

Local Institution - 0099, Arnhem, Not set

University Medical Center Groningen, Groningen, Not set

Szpital Specjalistyczny w Prabutach Spolka z o.o., Prabuty, Pomorskie

Przychodnia Lekarska KOMED, Konin, Wielkopolskie

Pratia Poznań, Poznań, Wielkopolskie

Centrum Onkologii im. Prof. Franciszka Lukaszczyka, Bydgoszcz, Not set

Instytut Centrum Zdrowia Matki Polki, Łódź, Łódzkie

SC Memorial Healthcare International SRL, Bucharest, București

Institutul Oncologic Bucuresti, Bucharest, București

SC Radiotherapy Center Cluj SRL, Florești, Cluj

Centrul de Oncologie "Sfântul Nectarie", Craiova, Dolj

Institutul Oncologic Cluj, Cluj, Not set

S.C. Centrul de Oncologie Euroclinic S.R.L., Iași, Not set

Institutul Regional de Oncologie, Iași, Not set

CHUS - Hospital Clinico Universitario, Santiago de Compostela, A Coruña [La Coruña]

Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña]

Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya [Cataluña]

Hospital Universitario de Jaen, Jaen, Jaén

Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De

Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Comunidad De

Hospital General Universitario de Valencia, Valencia, Valenciana, Comunitat

Local Institution - 0299, Sevilla, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Kantonsspital Graubünden, Chur, Not set

Kantonsspital Winterthur, Winterthur, Not set

UniversitätsSpital Zürich, Zürich, Not set

Local Institution - 0158, Cigli, İzmir

Local Institution - 0154, Adana, Not set

Local Institution - 0157, Ankara, Not set

Local Institution - 0177, Ankara, Not set

Local Institution - 0153, Istanbul, Not set

Local Institution - 0197, London, London, City Of

Local Institution - 0183, Central Middlesbrough, Middlesbrough

Local Institution - 0159, Aberdeen, Not set

Local Institution - 0108, Leicester, Not set

The Christie NHS Foundation Trust, Manchester, Not set

The Clatterbridge Cancer Centre, Wirral, Not set

Conditions: Extensive-Stage Small Cell Lung Cancer

Learn More ›

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438

Recruiting

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug) + chemotherapy, budigalimab +chemotherapy, or pembrolizumab +chemotherapy. In Stage 2, there are 2 treatments arms. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab +chemotherapy or placebo in combination with pembrolizumab +chemotherapy. Chemotherapy consists of IV Infused pemetrexed + IV infused cisplatin or IV infused or injected carboplatin. Approximately 840 adult participants will be enrolled in the study across 200 sites worldwide. Stage 1: In cohort 1, participants will receive intravenously (IV) infused livmoniplimab (dose A)+ IV infused budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + IV Infused pemetrexed. In cohort 2, participants will receive livmoniplimab (dose B) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In cohort 3, participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed . In cohort 4, participants will receive IV Infused pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. Stage 2: In arm 1, participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In arm 2, participants will receive IV Infused placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. The estimated study duration is 55 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/26/2025

Locations: Moores Cancer Center /ID# 267782, La Jolla, California +55 locations

Moores Cancer Center /ID# 267782, La Jolla, California

Memorial Hospital West /ID# 262221, Pembroke Pines, Florida

Bond Clinic /ID# 262611, Winter Haven, Florida

University Cancer & Blood Cent /ID# 261824, Athens, Georgia

The University of Chicago Medical Center /ID# 262259, Chicago, Illinois

University of Kansas Medical Center /ID# 263196, Westwood, Kansas

Baptist Health Lexington /ID# 261823, Lexington, Kentucky

Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids, Michigan

Washington University-School of Medicine /ID# 262759, Saint Louis, Missouri

Stony Brook Cancer Center /ID# 261954, Stony Brook, New York

Cone Health Cancer Center /ID# 262583, Greensboro, North Carolina

Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati, Ohio

Guthrie Robert Packer Hospital /ID# 262758, Sayre, Pennsylvania

Renovatio clinical /ID# 262000, El Paso, Texas

Houston Methodist Hospital /ID# 262722, Houston, Texas

Texas Oncology - Plano East /ID# 264356, Plano, Texas

Texas Oncology, P. A. /ID# 264311, San Antonio, Texas

Renovatio Clinical /ID# 261999, The Woodlands, Texas

Vista Oncology - East Olympia /ID# 262303, Olympia, Washington

The Canberra Hospital /ID# 261891, Garran, Australian Capital Territory

Nepean Hospital /ID# 262157, Kingswood, New South Wales

Westmead Hospital /ID# 261894, Westmead, New South Wales

Hospital La Louviere Site Jolimont - Helora /ID# 261269, La Louvière, Hainaut

AZ Maria Middelares /ID# 262313, Gent, Not set

Groupe Sante CHC - Clinique du MontLegia /ID# 262338, Liege, Not set

UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 262557, Namur, Not set

Centro de Investigacion y Desarrollo Oncologico /ID# 261800, Temuco, Araucania

Fundacion Arturo Lopez Perez /ID# 261700, Providencia, Region Metropolitana De Santiago

Oncored /Id# 261801, Vitacura, Region Metropolitana Santiago

Sociedad Cem-Cancer Spa /Id# 262316, Viña del Mar, Valparaíso

Hospital Clinico Universidad De Los Andes /ID# 262665, Santiago, Not set

APHM - Hopital Nord /ID# 261129, Marseille, Bouches-du-Rhone

CHU Grenoble - Hopital Michallon /ID# 261131, La Tronche, Isere

Centre Hosp Intercommunal de Creteil /ID# 261130, Creteil, Val-de-Marne

Rambam Health Care Campus /ID# 262431, Haifa, H_efa

Shaare Zedek Medical Center /ID# 262432, Jerusalem, Yerushalayim

National Cancer Center Hospital East /ID# 261923, Kashiwa-shi, Chiba

Saitama Cancer Center /ID# 262703, Kitaadachi-gun, Saitama

National Cancer Center Hospital /ID# 261925, Chuo-ku, Tokyo

Ziekenhuis St. Jansdal /ID# 261193, Harderwijk, Gelderland

Isala /ID# 262458, Zwolle, Overijssel

Pan American Center for Oncology Trials /ID# 269666, Rio Piedras, Not set

Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 262723, Santiago de Compostela, A Coruna

Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 262118, L'Hospitalet de Llobregat, Barcelona

UOMi Cancer Center - Clinica Tres Torres /ID# 262116, Barcelona, Not set

Hospital Universitario Vall d'Hebron /ID# 262113, Barcelona, Not set

Hospital General Universitario Gregorio Maranon /ID# 262114, Madrid, Not set

Hospital Universitario 12 de Octubre /ID# 262112, Madrid, Not set

Hospital Clinico Universitario de Valencia /ID# 262115, Valencia, Not set

National Cheng Kung University Hospital /ID# 262016, Tainan, Not set

Mackay Memorial Hospital /ID# 262534, Taipei City, Not set

Taipei Medical University Hospital /ID# 262020, Taipei City, Not set

Linkou Chang Gung Memorial Hospital /ID# 262535, Taoyuan City, Not set

Gazi University Medical Faculty /ID# 261786, Ankara, Not set

Ankara City Hospital /ID# 261785, Ankara, Not set

Dr. Suat Seren Gogus Has /ID# 261789, Izmir, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251

Recruiting

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Yale Cancer Center, New Haven, Connecticut +9 locations

Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer

Learn More ›

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076

Recruiting

The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Southern Cancer Center, PC, Daphne, Alabama +115 locations

Southern Cancer Center, PC, Daphne, Alabama

Clearview Cancer Institute, Huntsville, Alabama

Cancer Treatment Center of America Phoenix, Goodyear, Arizona

City of Hope Corona, Corona, California

City of Hope, Duarte, California

Providence Medical Foundation, Fullerton, California

The Oncology Institute of Hope and Innovation, Glendale, California

Oncology Physicians Network Healthcare, Glendale, California

Los Angeles Cancer Network, Glendale, California

Glendale Adventist Medical Center, Glendale, California

Marin Cancer Center, Greenbrae, California

City of Hope Seacliff, Huntington Beach, California

City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

City of Hope Antelope Valley, Lancaster, California

City of Hope Long Beach Elm, Long Beach, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

Cedars Sinai Medical Center, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Valkyrie Clinical Trials, Murrieta, California

Kaiser Permanente Oakland Medical Center, Oakland, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

University of California Irvine, Orange, California

Kaiser Permanente Roseville Medical Center, Roseville, California

Sutter Institute for Medical Research, Sacramento, California

Kaiser Permanente San Francisco Medical Center, San Francisco, California

UCSF Zuckerberg San Francisco General Hospital, San Francisco, California

Sansum Clinic, Santa Barbara, California

Kaiser Permanente Santa Clara Medical Center, Santa Clara, California

Providence Medical Foundation, Santa Rosa, California

City of Hope South Pasadena, South Pasadena, California

City of Hope Upland, Upland, California

Kaiser Permanente Northern California, Vallejo, California

Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, California

John Muir Health Clinical Research Center, Walnut Creek, California

Rocky Mountain Cancer Centers, Lone Tree, Colorado

Yale New Haven Hospital Yale Cancer Center, New Haven, Connecticut

ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark, Delaware

MedStar Georgetown University Hospital, Washington, District of Columbia

Washington DC VA Medical Center, Washington, District of Columbia

Baptist Lynn Cancer Institute, Boca Raton, Florida

The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida

AdventHealth Orlando, Orlando, Florida

Orlando Health Cancer Institute, Orlando, Florida

Moffitt Cancer Center, Tampa, Florida

University Cancer And Blood Center LLC, Athens, Georgia

Grady Health System Correll Pavilion, Atlanta, Georgia

Piedmont Healthcare, Atlanta, Georgia

Piedmont Cancer Institute, Atlanta, Georgia

Winship Cancer Institute Emory University, Atlanta, Georgia

City of Hope Cancer Center, Newnan, Georgia

University of Illinois at Chicago, Chicago, Illinois

Cancer Care Specialists of Central Illinois, Decatur, Illinois

Hope and Healing Cancer Services, Hinsdale, Illinois

Illinois Cancer Specialists, Niles, Illinois

City of Hope Chicago, Zion, Illinois

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

Investigative Clinical Research of Indiana, LLC, Noblesville, Indiana

Accellacare of McFarland, Ames, Iowa

Maryland Oncology Hematology P A, Silver Spring, Maryland

Boston University Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti, Michigan

University Of Minnesota, Minneapolis, Minnesota

Jackson Oncology Associates, Jackson, Mississippi

Truman Medical Ctr West, Kansas City, Missouri

Washington University School Of Medicine, Saint Louis, Missouri

Oncology Hematology Associates, Springfield, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hunterdon Hematology Oncology, Flemington, New Jersey

Morristown Medical Center, Morristown, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Overlook Medical Center, Summit, New Jersey

Holy Name Medical Center, Teaneck, New Jersey

University of New Mexico, Albuquerque, New Mexico

Montefiore Medical Center, Bronx, New York

Hematology-Oncology Associates of CNY, East Syracuse, New York

Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York

NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York, New York

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York

Ellis Hospital, Schenectady, New York

New York Cancer and Blood Specialists, Shirley, New York

Clinical Research Alliance Inc, Westbury, New York

Regional Medical Oncology Center, Wilson, North Carolina

University of Cincinnati, Cincinnati, Ohio

Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene, Oregon

Oregon Health And Science University, Portland, Oregon

Lankenau Institute for Medical Research Main Line Health Bryn Mawr Hospital, Bryn Mawr, Pennsylvania

Lankenau Institute for Medical Research Main Line Health Paoli Hospital, Paoli, Pennsylvania

Philadelphia VA Medical Center, Philadelphia, Pennsylvania

McGlinn Cancer Institute Reading Hospital, West Reading, Pennsylvania

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

Tennessee Oncology, Chattanooga, Tennessee

University of Tennessee, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Tennessee Oncology, Nashville, Tennessee

Texas Oncology P A, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

Renovatio Clinical, El Paso, Texas

JPS Health Network, Fort Worth, Texas

MD Anderson Cancer Center, Houston, Texas

Oncology Consultants Texas, Houston, Texas

Community Clinical Trials, Kingwood, Texas

Texas Oncology Odessa-West Texas Cancer Center, Odessa, Texas

Renovatio Clinical, The Woodlands, Texas

The University of Texas Health Science Center at Tyler, Tyler, Texas

Texas Oncology-Gulf Coast, Webster, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Vista Oncology, Olympia, Washington

Summit Cancer Centers, Spokane, Washington

Northwest Cancer Specialists - Vancouver, Vancouver, Washington

Auxilio Mutuo Cancer Center, San Juan, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Plasma-Adapted First-Line Pembro In NSCLC

NCT04166487

Active Not Recruiting

This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and use that information to determine whether patients should continue treatment with pembrolizumab or switch treatment to pembrolizumab in combination with chemotherapy. The names of the study drugs involved in this study are: * Pembrolizumab * Platinum doublet chemothera... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Brigham and Women's Hospital, Boston, Massachusetts +4 locations

Conditions: NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer

Learn More ›

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985

Active Not Recruiting

This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: City of Hope, Duarte, California +6 locations

Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer

Learn More ›

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT06624059

Recruiting

The objective of this study is to evaluate the efficacy and/or safety of multiple therapies in patients with early-stage resectable NSCLC. Cohort B1 is a phase II cohort that will evaluate the safety, and efficacy of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection. Cohort B2 is a phase II cohort that will evaluate the efficacy and safety of perioperative alectinib in combination with chemotherapy in the neoad... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Clinical Research Alliance, Westbury, New York +26 locations

Clinical Research Alliance, Westbury, New York

Royal North Shore Hospital, St. Leonards, New South Wales

Calvary Mater Newcastle, Waratah, New South Wales

Peter Maccallum Cancer Centre, Melbourne, Victoria

Sir Charles Gairdner Hospital, Nedlands, Western Australia

Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul

Hospital de Cancer de Barretos, Barretos, São Paulo

Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, São Paulo

Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo

K2 Oncology, Providencia, Not set

RedSalud Vitacura, Santiago, Not set

Beijing Cancer Hospital, Beijing, Not set

Xiangya Hospital of Centre-South University, Changsha, Not set

The third people's hospital of Chengdu, Chengdu, Not set

Guangdong General Hospital, Guangzhou, Not set

Jinhua municipal central hospital, Jinhua, Not set

Yunnan Cancer Hospital, Kunming, Not set

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, Not set

Zhejiang Cancer Hospital, Zhejiang, Not set

Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia, Perugia, Umbria

St. Vincent's Hospital, Gyeonggi-do, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Hospital Regional Universitario Carlos Haya, Malaga, Not set

Oncology Unit, Faculty of Medicine, Vajira Hospital, Dusit, Not set

Srinagarind Hospital, Khon Kaen, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Recruiting

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: University of Connecticut Health Center, Farmington, Connecticut +8 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Browse by State

Carboplatin treatment options in Alabama

Carboplatin treatment options in Alaska

Carboplatin treatment options in Arizona

Carboplatin treatment options in Arkansas

Carboplatin treatment options in California

Carboplatin treatment options in Colorado

Carboplatin treatment options in Connecticut

Carboplatin treatment options in Delaware

Carboplatin treatment options in District of Columbia

Carboplatin treatment options in Florida

Carboplatin treatment options in Georgia

Carboplatin treatment options in Hawaii

Carboplatin treatment options in Idaho

Carboplatin treatment options in Illinois

Carboplatin treatment options in Indiana

Carboplatin treatment options in Iowa

Carboplatin treatment options in Kansas

Carboplatin treatment options in Kentucky

Carboplatin treatment options in Louisiana

Carboplatin treatment options in Maine

Carboplatin treatment options in Montana

Carboplatin treatment options in Nebraska

Carboplatin treatment options in Nevada

Carboplatin treatment options in New Hampshire

Carboplatin treatment options in New Jersey

Carboplatin treatment options in New Mexico

Carboplatin treatment options in New York

Carboplatin treatment options in North Carolina

Carboplatin treatment options in North Dakota

Carboplatin treatment options in Ohio

Carboplatin treatment options in Oklahoma

Carboplatin treatment options in Oregon

Carboplatin treatment options in Maryland

Carboplatin treatment options in Massachusetts

Carboplatin treatment options in Michigan

Carboplatin treatment options in Minnesota

Carboplatin treatment options in Mississippi

Carboplatin treatment options in Missouri

Carboplatin treatment options in Pennsylvania

Carboplatin treatment options in Rhode Island

Carboplatin treatment options in South Carolina

Carboplatin treatment options in South Dakota

Carboplatin treatment options in Tennessee

Carboplatin treatment options in Texas

Carboplatin treatment options in Utah

Carboplatin treatment options in Vermont

Carboplatin treatment options in Virginia

Carboplatin treatment options in Washington

Carboplatin treatment options in West Virginia

Carboplatin treatment options in Wisconsin

Carboplatin treatment options in Wyoming